Brain shuttle field accelerates with three more pharma deals

Three deals in two weeks add to the momentum for blood-brain barrier shuttle technologies capable of delivering proteins and RNA oligonucleotides into the CNS. They also showcase differentiation beyond the transferrin receptor, the field’s most commonly used portal into the brain.

On Wednesday, South Korea-based ABL Bio Inc. (KOSDAQ:298380) announced its second deal this year with a major pharma, and third since 2022, employing its Grabody-B platform, which uses the IGF1 receptor, rather than the TfR, as a portal for transporting biologics across the blood-brain barrier (BBB)...